CELG - Celgene Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
89.62
-1.39 (-1.53%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close91.01
Open90.85
Bid0.00 x 0
Ask0.00 x 0
Day's Range89.27 - 91.80
52 Week Range84.25 - 147.17
Volume3,598,870
Avg. Volume7,678,514
Market Cap67.41B
Beta1.31
PE Ratio (TTM)24.62
EPS (TTM)3.64
Earnings DateMay 4, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est115.62
Trade prices are not sourced from all markets
  • MARKETS: Today's winning stocks are more interesting than the losers, like Procter & Gamble
    Yahoo Finance Video9 hours ago

    MARKETS: Today's winning stocks are more interesting than the losers, like Procter & Gamble

    Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.

  • Business Wire8 hours ago

    Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Celgene Corporation (CELG) and Encourages Investors to Contact the Firm

    Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired Celgene Corporation securities between September 12, 2016 and February 27, 2018 .

  • Top Research Reports for IBM, McDonald's & Gilead
    Zacks10 hours ago

    Top Research Reports for IBM, McDonald's & Gilead

    Top Research Reports for IBM, McDonald's & Gilead

  • Business Wire18 hours ago

    Celgene Corporation Announces Changes to Its Board of Directors

    Gilla Kaplan, Ph.D., Celgene’s longest-standing Director, is retiring from the Board and will not stand for reelection at the upcoming Annual Meeting of Stockholders to be held on June 13, 2018. Patricia “Pat” Hemingway Hall and Hans Bishop have been elected to Celgene’s Board of Directors. Dr. Kaplan has served as Director since April 1998.

  • Gilead Sciences Expects Decline in Earnings in Fiscal 2018
    Market Realist18 hours ago

    Gilead Sciences Expects Decline in Earnings in Fiscal 2018

    Gilead Sciences (GILD) expects to witness non-GAAP gross product margin in the range of 85% to 87% in fiscal 2018. The company has also projected non-GAAP research and development (or R&D) and selling, general, and administrative (or SG&A) expenses in the range of $3.4 billion to $3.6 billion, respectively. The company has also projected a diluted earnings per share (or EPS) impact of $0.41 to $1.51, attributable to stock-based compensation paid for acquisitions and other related expenses.

  • Vyxeos Could Be Jazz Pharmaceuticals’ Long-Term Growth Driver
    Market Realist18 hours ago

    Vyxeos Could Be Jazz Pharmaceuticals’ Long-Term Growth Driver

    In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Vyxeos (daunorubicin and cytarabine) generated revenues of $24 million compared to $10 million in 3Q17. In fiscal 2017, Vyxeos reported net revenues of $34 million.

  • Moody's21 hours ago

    Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising

    The global pharmaceutical industry will see annual earnings growth of 1%-2% over the next 12 to 18 months, supporting a stable outlook on the sector, Moody's Investors Service says in its just-released report. The rating agency's stable outlook and modest EBITDA growth reflect solid underlying fundamentals, including rising utilization of prescription drugs, expansion in emerging markets and positive pricing trends in the US in many therapeutic areas. Among the diverse group of pharmaceutical companies rated by Moody's, those focusing on cancer drugs will see the highest EBITDA growth of more than 10%, while companies with a strong portfolio of products treating rare diseases will see solid growth in the 6%-10% range.

  • Gilead Sciences May Witness Significant Drop in Revenues in 2018
    Market Realistyesterday

    Gilead Sciences May Witness Significant Drop in Revenues in 2018

    Gilead Sciences (GILD) expects to report net product sales in the range of $20.0 billion to $21.0 billion for full-year 2018. Compared to fiscal 2017, the company anticipates a negative impact attributable to declining hepatitis C (or HCV) drug sales in the range $5.1 billion to $5.6 billion in fiscal 2018. Additionally, Gilead Sciences has also projected a negative top-line impact in the range of $0.8 billion to $0. ...

  • What Analysts Recommend for Gilead Sciences in April 2018
    Market Realistyesterday

    What Analysts Recommend for Gilead Sciences in April 2018

    In 4Q17, Gilead Sciences (GILD) reported revenues close to $5.9 billion, which is a year-over-year (or YoY) drop of around 19%. Gilead Sciences reported net product sales close to $5.8 billion in 4Q17, which is a YoY decline of 19% and a quarter-over-quarter drop close to 9%. The company also reported net product sales close to $25.7 billion for fiscal 2017, which is a YoY decline of around 14%.

  • Investopediayesterday

    Why Big Biotech Stocks May Get An Earnings Boost

    Big Bounce: Big biotech stocks may surge on better-than-expected quarterly results

  • ETF Trends2 days ago

    Big Biotech ETF Can Bounce Back

    The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), the largest biotech exchange traded fund by assets, and other biotechnology assets have recently been slumping, but some analysts believe big biotechnology ...

  • Risankizumab Could Be AbbVie’s Long-Term Growth Driver
    Market Realist3 days ago

    Risankizumab Could Be AbbVie’s Long-Term Growth Driver

    In December 2017, AbbVie (ABBV) announced positive top-line results for its pivotal Phase 3 IMMhance trial to evaluate the safety and efficacy of risankizumab 150 mg1 for the treatment of individuals with moderate-to-severe plaque psoriasis.

  • GlobeNewswire3 days ago

    New Research: Key Drivers of Growth for Johnson & Johnson, Chesapeake Energy, Visa, Celgene, Adobe, and Markel — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, April 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • Business Wire3 days ago

    Celgene Corporation to Webcast at Upcoming Investor Conferences

    Celgene Corporation plans to present at three upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company’s website at www.celgene.com.